2–4 weeks after the administration of EAAL cells, the subsets of CD3+CD8+ T lymphocytes and CD3−CD56+ NK cells in the PB were increased significantly in comparison with those before the therapy. Moreover, the percentage of IFN-γ producing cells of the CD3+, CD8+ and CD3− subsets after infusion were all increased significantly, which indicated that EAAL therapy was able to enrich the potentially anti-tumor cytotoxic PB lymphocytes. The gene discussed is CD8A; the disease is neoplasm.